SOPs for Drug Discovery

The purpose of this Standard Operating Procedure (SOP) is to establish the process for proper documentation and record-keeping throughout drug discovery projects. Accurate and thorough documentation is essential for regulatory compliance, maintaining data integrity, ensuring reproducibility, and facilitating effective communication among project teams. This SOP ensures that all data, protocols, experimental results, and project-related documents are consistently captured, stored, and accessible for future reference.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to outline the process for preparing and submitting drug discovery proposals within the drug development organization. These proposals are essential for securing funding, initiating new drug discovery projects, and establishing project timelines, budgets, and objectives. This SOP ensures that all drug discovery proposals are thoroughly prepared, scientifically sound, and aligned with organizational goals and regulatory requirements.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to define the process for managing and sharing knowledge in drug discovery projects. Effective knowledge management ensures that valuable scientific data, research findings, intellectual property, and project insights are systematically captured, stored, and disseminated across teams. This SOP ensures that knowledge management practices are consistently followed, facilitating better decision-making and collaboration throughout the drug discovery process.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to outline the process for conducting early-stage patent analysis of drug candidates during the drug discovery phase. Patent analysis helps identify the intellectual property landscape around a drug candidate, determine its patentability, and assess potential patent risks. This SOP ensures that patent analysis is conducted systematically, using reliable resources and methods to support decision-making in drug development.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to define the process for collaborating with Contract Research Organizations (CROs) in drug discovery. CROs provide specialized expertise and resources to support various stages of the drug discovery process, including preclinical research, clinical trials, and regulatory submissions. This SOP ensures that collaborations with CROs are conducted efficiently, with clear expectations and aligned goals, while maintaining quality and compliance with regulatory requirements.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to outline the use of computational tools in the analysis of target pathways during drug discovery. Understanding the molecular pathways and interactions involved in disease mechanisms is critical for identifying potential therapeutic targets. Computational tools can analyze biological networks, predict key molecular interactions, and help identify novel drug targets. This SOP ensures that computational tools are used systematically and effectively to support drug discovery by providing insights into target pathway analysis.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to outline the process for conducting high-content screening (HCS) methods in drug discovery. HCS is a powerful technique that allows for the simultaneous measurement of multiple cellular events, providing comprehensive insights into drug effects on cellular morphology, viability, and other cellular parameters. This SOP ensures that HCS experiments are performed systematically, yielding reproducible and high-quality data for the identification of novel drug candidates.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to outline the process for screening enzyme inhibitors in drug discovery. Enzyme inhibitors are crucial tools in developing therapeutic agents for diseases where enzymes play a key role in disease progression. This SOP ensures that enzyme inhibitor screening is conducted systematically and that the results are reliable, reproducible, and interpretable to identify promising drug candidates for further development.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to describe the process of identifying early-stage biomarkers in drug discovery. Biomarkers are biological molecules or indicators that provide insight into disease progression, drug efficacy, and safety. Early-stage biomarker identification plays a critical role in the development of novel therapeutic candidates, guiding both preclinical and clinical development stages. This SOP ensures that biomarkers are identified systematically, reliably, and reproducibly, supporting the discovery of promising drug candidates.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to outline the process for conducting preclinical efficacy studies using cell lines in drug development. Preclinical efficacy studies assess the biological activity and potential therapeutic effects of drug candidates in vitro, providing important insights into their mechanism of action and therapeutic potential. This SOP ensures that these studies are conducted systematically, with accurate and reproducible results to support further drug development and clinical trials.
Click to read the full article.